Plasma C-reactive protein and risk of breast cancer in two prospective studies and a metaanalysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 8, 2015, Pages 1199-1206

  Wang, Jun ^a   Lee, I Min ^b,c   Tworoger, Shelley S ^b,c   Buring, Julie E ^b,c   Ridker, Paul M ^b   Rosner, Bernard ^b,c   Hankinson, Susan E ^a,b,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR INVASION; BLOOD; BREAST TUMOR; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84941767271     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0187     Document Type: Article

References (45)

1. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. JClin Invest 2003;111:1805-12.
2. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
3. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
4. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3-13.
5. Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205.
6. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24:5216-22.
7. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, Creactive protein, and risk of lung cancer. J Natl Cancer Inst 2011;103: 1112-22.
8. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
9. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4.
10. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 2013;105:1871-80.
11. Poole EM, Lee IM, Ridker PM, Buring JE, Hankinson SE, Tworoger SS. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor alpha receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 2013;178:1256-64.
12. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90.
13. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF,Weinstein S, Wood RJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-7.
14. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690-5.
15. Gaudet MM, Patel AV, Teras LR, Sun J, Campbell PT, Stevens VL, et al. Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet 2013;4:156-66.
16. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, et al. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat 2012;133:1077-88.
17. Ollberding NJ, Kim Y, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res 2013;6:188-95.
18. Zeleniuch-Jacquotte A,Gu Y, Bruning PF, Bonfrer JM, Koenig KL, Arslan AA, et al. Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2008;100:443-4; author reply 4-5.
19. Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K, Joshu CE, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 2013;24:2077-87.
20. Wang G, Li N, Chang S, Bassig BA, Guo L, Ren J, et al. A prospective followup study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev 2015;24:459-65. doi: 10.1158/1055-9965. Epub 2014 Dec 9.
21. Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, Blamey RW, et al. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 1995;21:504-9.
22. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27: 3437-44.
23. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 2011;13:R55.
24. Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS, et al. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 2007;96:891-5.
25. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 2008;17:1719-22.
26. Ling J, Kumar R. Crosstalk between NF-kB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett 2012;322:119-26.
27. Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 2002;13:669-78.
28. Zhang SM, Lin J, Cook NR, Lee IM, Manson JE, Buring JE, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst 2007;99:890-4.
29. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87: 1297-302.
30. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
31. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women'sHealth Study: a randomized controlled trial. JAMA 2005;294:47-55.
32. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women'sHealth Study: a randomized controlled trial. JAMA 2005;294: 56-65.
33. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002;136:529-33.
34. Rosner B. Percentage points for a generalized ESDmany-outlier procedure. Technometrics 1983;25:165-72.
35. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 2008;167:653-66.
36. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003;107:645-51.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
38. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, Binda E, et al. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2011;20:428-37.
39. Dossus L, Jimenez-Corona A, Romieu I, Boutron-Ruault MC, Boutten A, Dupre T, et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control 2014;25:533-9.
40. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res 2003;11:1055-64.
41. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
42. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
43. Llanos AA, Dumitrescu RG, Marian C, Makambi KH, Spear SL, Kallakury BV, et al. Adipokines in plasma and breast tissues: associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev 2012;21:1745-55.
44. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9.
45. Catsburg C, Gunter MJ, Chen C, Cote ML, Kabat GC, Nassir R, et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74:3248-58.